SGLT2i use linked to lower risk for neurodegenerative disease in T2DM
By
HealthDay News
Sep 18, 2024
A reduced risk for Alzheimer’s disease, vascular dementia and Parkinson’s disease was seen with SGLT2i use in type 2 diabetes.
Racial differences seen in pain Rx for older adults with hip fracture
By
HealthDay News
Sep 12, 2024
Black beneficiaries have lower average doses in the first 90 days.
Once-weekly efsitora noninferior to degludec for type 2 diabetes
By
HealthDay News
Sep 13, 2024
Once-weekly efsitora was noninferior to once-daily degludec for a decrease in the mean glycated hemoglobin level.
No spike in schizophrenia, other diagnoses among people with dementia after feds crack down on antipsychotic...
By
Kimberly Marselas
Aug 28, 2024
Federal policies designed to reduce use of antipsychotic medications in nursing homes did not lead to clinically significantly higher rates of schizophrenia diagnoses among people living with dementia,...
Low-dose triple-pill protocol lowers BP in Black Africans with hypertension
By
Haymarket Media
Sep 10, 2024
The mean home systolic blood pressure was lower with the triple-pill protocol versus the standard-care protocol at month 6.
New deals will cut Medicare costs for expensive drugs
Aug 15, 2024
The Biden administration said Thursday that it has signed deals with drug companies that will lower the prices on 10 of the most popular and expensive drugs used by American seniors.
Adjunctive IV argatroban, eptifibatide do not cut disability after stroke
By
Haymarket Media
Sep 06, 2024
The findings were seen among patients with acute ischemic stroke who were treated with intravenous thrombolysis within three hours after symptom onset.
Is Eli Lilly using ‘granfluencers’ to raise awareness of its Alzheimer’s med?
By
Marc Iskowitz
Sep 04, 2024
Here’s why older internet celebs — granfluencers — soon might be making rounds on the Alzheimer’s drug marketing scene.
Time from drug approval to reimbursement longer in US than some European countries
By
Haymarket Media
Sep 03, 2024
France has highest reimbursement rate one month after approval, while U.S. and Germany had no drugs reimbursed at one month
Risk for dementia similar with SGLT2 inhibitors, dulaglutide in T2DM
Aug 26, 2024
The estimated risk difference varied from −2.45 to 0.63 percentage points with SGLT2 versus dulaglutide among older adults.